The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 25, 2023

Filed:

Jan. 18, 2017
Applicant:

Biodesix, Inc., Boulder, CO (US);

Inventors:

Arni Steingrimsson, Steamboat Springs, CO (US);

Carlos Oliveira, Steamboat Springs, CO (US);

Krista Meyer, Steamboat Springs, CO (US);

Joanna Röder, Steamboat Springs, CO (US);

Heinrich Röder, Steamboat Springs, CO (US);

Assignee:

BIODESIX, INC., Boulder, CO (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/48 (2006.01); G16B 40/20 (2019.01); G16B 40/00 (2019.01); G16H 50/70 (2018.01); C12Q 1/68 (2018.01); A61K 39/00 (2006.01); G16H 20/17 (2018.01); G01N 33/68 (2006.01); H01J 49/00 (2006.01);
U.S. Cl.
CPC ...
G16B 40/20 (2019.02); A61K 39/00 (2013.01); C12Q 1/68 (2013.01); G01N 33/6848 (2013.01); G16B 40/00 (2019.02); G16H 20/17 (2018.01); G16H 50/70 (2018.01); H01J 49/0036 (2013.01); G01N 2800/52 (2013.01);
Abstract

A method is disclosed for predicting in advance whether a melanoma patient is likely to benefit from high dose IL2 therapy in treatment of the cancer. The method makes use of mass spectrometry data obtained from a blood-based sample of the patient and a computer configured as a classifier and making use of a reference set of mass spectral data obtained from a development set of blood-based samples from other melanoma patients. A variety of classifiers for making this prediction are disclosed, including a classifier developed from a set of blood-based samples obtained from melanoma patients treated with high dose IL2 as well as melanoma patients treated with an anti-PD-1 immunotherapy drug. The classifiers developed from anti-PD-1 and IL2 patient sample cohorts can also be used in combination to guide treatment of a melanoma patient.


Find Patent Forward Citations

Loading…